Marcel Tomaszewski1, Monica Dahiya2, Seyed Amir Mohajerani3, Hanaa Punja4, Hin Hin Ko5, Muxin Sun6, Alnoor Ramji1. 1. Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 2. Faculty of Medicine, University of Alberta., Edmonton, Alberta, Canada. 3. Saint Paul's Hospital, Gastrointestinal Research Institute, Vancouver, British Columbia, Canada. 4. Department of Biology, University of British Columbia, Vancouver, British Columbia, Canada. 5. Clinical Associate Professor of Medicine, Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 6. Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
INTRODUCTION: To determine predictors of hepatic steatosis by the computed attenuation parameter (CAP) and fibrosis via transient elastography (TE) in persons on methotrexate (MTX) therapy with rheumatologic and dermatologic diseases. METHODS: A single-centred retrospective cohort study was performed. Patients on >6 months of MTX for a rheumatologic or dermatologic disease who had undergone TE from January 2015 to September 2019 were included. Multivariate analysis was performed to determine predictors of steatosis and fibrosis. RESULTS: A total of 172 patients on methotrexate were included. Psoriasis was the most frequent diagnosis (n = 55), followed by rheumatoid arthritis (n = 45) and psoriatic arthritis (n = 34). Steatosis (CAP ≥245 dB/m) was present in 69.8% of patients. Multivariate regression analysis revealed that diabetes mellitus (OR 10.47, 95% CI 1.42-75.35), hypertension (OR 5.15, 95% CI 1.75-15.38), and BMI ≥30 kg/m2 (OR 16.47, 95% CI 5.56-45.56) were predictors of steatosis (CAP ≥245 dB/m). Predictors of moderate to severe fibrosis (Metavir ≥F2 = TE ≥8.0 kPa) by multivariate regression analysis included moderate to severe steatosis (CAP ≥270 dB/m) (OR 8.36, 95% CI 1.88-37.14), diabetes mellitus (OR 2.85, 95% CI 1.09-7.48), hypertension (OR 5.4, 95% CI 2.23-13.00), dyslipidemia (OR 3.71, 95% CI 1.50-9.18), and moderate alcohol use (OR 3.06, 95% CI 1.2-7.49). CONCLUSIONS: In patients on MTX for rheumatologic and dermatologic diseases, hepatic steatosis as measured by CAP was common and moderate to severe steatosis predicted moderate to severe fibrosis.
INTRODUCTION: To determine predictors of hepatic steatosis by the computed attenuation parameter (CAP) and fibrosis via transient elastography (TE) in persons on methotrexate (MTX) therapy with rheumatologic and dermatologic diseases. METHODS: A single-centred retrospective cohort study was performed. Patients on >6 months of MTX for a rheumatologic or dermatologic disease who had undergone TE from January 2015 to September 2019 were included. Multivariate analysis was performed to determine predictors of steatosis and fibrosis. RESULTS: A total of 172 patients on methotrexate were included. Psoriasis was the most frequent diagnosis (n = 55), followed by rheumatoid arthritis (n = 45) and psoriatic arthritis (n = 34). Steatosis (CAP ≥245 dB/m) was present in 69.8% of patients. Multivariate regression analysis revealed that diabetes mellitus (OR 10.47, 95% CI 1.42-75.35), hypertension (OR 5.15, 95% CI 1.75-15.38), and BMI ≥30 kg/m2 (OR 16.47, 95% CI 5.56-45.56) were predictors of steatosis (CAP ≥245 dB/m). Predictors of moderate to severe fibrosis (Metavir ≥F2 = TE ≥8.0 kPa) by multivariate regression analysis included moderate to severe steatosis (CAP ≥270 dB/m) (OR 8.36, 95% CI 1.88-37.14), diabetes mellitus (OR 2.85, 95% CI 1.09-7.48), hypertension (OR 5.4, 95% CI 2.23-13.00), dyslipidemia (OR 3.71, 95% CI 1.50-9.18), and moderate alcohol use (OR 3.06, 95% CI 1.2-7.49). CONCLUSIONS: In patients on MTX for rheumatologic and dermatologic diseases, hepatic steatosis as measured by CAP was common and moderate to severe steatosis predicted moderate to severe fibrosis.
Authors: Chi Chiu Mok; Gary Tin Choi Ko; Ling Yin Ho; Ka Lung Yu; Pak To Chan; Chi Hung To Journal: Arthritis Care Res (Hoboken) Date: 2011-02 Impact factor: 4.794
Authors: Vivian P Bykerk; Pooneh Akhavan; Glen S Hazlewood; Orit Schieir; Anne Dooley; Boulos Haraoui; Majed Khraishi; Sharon A Leclercq; Jean Légaré; Diane P Mosher; James Pencharz; Janet E Pope; John Thomson; Carter Thorne; Michel Zummer; Claire Bombardier Journal: J Rheumatol Date: 2011-09-15 Impact factor: 4.666
Authors: Joshua F Baker; Brian Sauer; Chia-Chen Teng; Michael George; Grant W Cannon; Said Ibrahim; Amy Cannella; Bryant R England; Kaleb Michaud; Liron Caplan; Lisa A Davis; James OʼDell; Ted R Mikuls Journal: J Clin Rheumatol Date: 2018-06 Impact factor: 3.517
Authors: Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs Journal: Hepatology Date: 2004-12 Impact factor: 17.425
Authors: R Candia; A Ruiz; R Torres-Robles; N Chávez-Tapia; N Méndez-Sánchez; M Arrese Journal: J Eur Acad Dermatol Venereol Date: 2014-11-21 Impact factor: 6.166
Authors: Eva Klingberg; Annelie Bilberg; Sofia Björkman; Martin Hedberg; Lennart Jacobsson; Helena Forsblad-d'Elia; Hans Carlsten; Björn Eliasson; Ingrid Larsson Journal: Arthritis Res Ther Date: 2019-01-11 Impact factor: 5.156